Compare VALE & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VALE | ZTS |
|---|---|---|
| Founded | 1942 | 1952 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.5B | 53.9B |
| IPO Year | N/A | 2013 |
| Metric | VALE | ZTS |
|---|---|---|
| Price | $13.98 | $127.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | $13.60 | ★ $174.60 |
| AVG Volume (30 Days) | ★ 29.4M | 5.8M |
| Earning Date | 02-18-2026 | 02-12-2026 |
| Dividend Yield | ★ 6.46% | 1.67% |
| EPS Growth | N/A | ★ 11.64 |
| EPS | 1.32 | ★ 5.94 |
| Revenue | ★ $40,027,019,862.00 | $9,397,000,000.00 |
| Revenue This Year | N/A | $3.04 |
| Revenue Next Year | $5.06 | $4.98 |
| P/E Ratio | ★ $10.51 | $21.42 |
| Revenue Growth | 1.05 | ★ 2.68 |
| 52 Week Low | $8.06 | $115.25 |
| 52 Week High | $14.38 | $177.40 |
| Indicator | VALE | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 65.73 | 56.19 |
| Support Level | $13.76 | $124.55 |
| Resistance Level | $14.38 | $131.13 |
| Average True Range (ATR) | 0.23 | 2.55 |
| MACD | 0.08 | 0.52 |
| Stochastic Oscillator | 76.51 | 63.14 |
Vale is a large global miner and the world's largest producer of iron ore and pellets. In recent years the company has sold noncore assets such as its fertilizer, coal, and steel operations to concentrate on iron ore, nickel, and copper. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets. The base metals division is much smaller, consisting of nickel mines and smelters along with copper mines producing copper in concentrate. In 2024, Vale sold a minority 10% stake in energy transition metals, its base metals business, likely the first step in separating base metals and iron ore.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.